ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 4 55-4, 2004, Pages

  Tiefenbacher, Christiane P ^a   Friedrich, Stefanie ^a   Bleeke, Tina ^a   Vahl, Christian ^a   Chen, Xiaobo ^a   Niroomand, Feraydoon ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Nitric oxide; Vasoconstriction relaxation

Indexed keywords

ACETYLCHOLINE; BRADYKININ ANTAGONIST; CANDESARTAN; DICHLOROISOCOUMARINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; FLUINDOSTATIN; HISTAMINE; HOE 130; LISINOPRIL; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; SEROTONIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIOLE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY VASCULAR RESISTANCE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HEART VALVE REPLACEMENT; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; VASODILATATION;

ACETYLCHOLINE; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOLES; ARTERIOSCLEROSIS; BENZIMIDAZOLES; CORONARY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; FEMALE; HISTAMINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LISINOPRIL; MALE; MIDDLE AGED; MUSCLE CONTRACTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITROPRUSSIDE; SEROTONIN; TETRAZOLES; VASCULAR DISEASES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 1642381855     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00783.2003     Document Type: Article

References (38)

1. Chilian WM, Dellsperger KC, Layne SM, Eastham CL, Armstrong MA, Marcus ML, and Heistad DD. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol Heart Circ Physiol 258: H529-H539, 1990.
2. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, and Dzau VJ. Hypercholesteremia attenuates endothelium-mediated vasodilation in man. J Clin Invest 86: 228-234, 1990.
3. Dobrucki LW, Kalinowski L, Dobrucki IT, and Malinski T. Statin-stimulated nitric oxide release from endothelium. Med Sci 7: 622-627, 2001.
4. Dupuis J, Tardif JC, Cernacek P, and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischaemia and function of the endothelium) trial. Circulation 99: 3227-3233, 1999.
5. Hattori Y, Nakanishi N, and Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res 54: 649-665, 2001.
6. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawic MA, Nour KR, and Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106: 653-658, 2002.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002.
8. Hecker M, Bara AT, and Busse R. Relaxation of isolated coronary arteries by angiotensin-converting enzyme inhibitors: role of endothelium-derived kinins. J Vasc Res 30: 257-262, 1993.
9. a. HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril), and vitamin E in patients at high risk of cardiovascular events The HOPE study investigators. Can J Cardiol 12: 127-137, 1996.
10. Hornig B, Kohler C, and Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95: 1115-1118, 1997.
11. Ikeda U, Shimpo M, Ikeda M, Minota S, and Shimada K. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 38: 69-77, 2001.
12. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998.
13. Kuo L, Davis MJ, Cannon S, and Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. Circ Res 70: 465-476, 1992.
14. Kuo L, Davis MJ, and Chilian WM. Endothelium-dependent, flow-induced dilation of isolated coronary arterioles. Am J Physiol Heart Circ Physiol 259: H1063-H1070, 1990.
15. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942: 23-30, 2002.
16. Laufs U and Liao JK. Targeting Rho in cardiovascular disease. Circ Res 87: 526-528, 2000.
17. Linz W, Wiemer G, Gohlke P, Unger T, and Schölkens PA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49, 1995.
18. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, and Ganz P. Paradoxical vasoconstriction induced by acetlycholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051, 1986.
19. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MJ, Haber HE, Uprichard AC, Pepine CJ, and Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 94: 258-265, 1996.
20. Mira ML, Silva MM, Queiroz MJ, and Manso CF. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun 19: 173-181, 1993.
21. Nakamura K, Al-Ruzzeh S, Chester AH, Schmidt I, Barbir M, Yacoub MH, and Amrani M. Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries. Ann Thorac Surg 73: 1860-1865, 2002.
22. Nickenig G, Stablein A, Wassmann S, Wyen C, Muller C, and Bohm M. Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 1: 361-364, 2000.
23. Penny WF, Ben-Yehuda O, Kuroe K, Long J, Bond A, Bhargave V, Peterson JF, Mc Daniel M, Juliano J, Witzum JL, Ross J Jr, and Peterson KL. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 37: 766-774, 2001.
24. Prasad A, Halcox JP, Waclawiw MA, and Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 8: 89-95, 2001.
25. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990. Nature 362: 801-809, 1993.
26. Schächinger V, Britten MB, and Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 948-954, 2001.
27. Schiffrin EL, Park JB, Intengan HD, and Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101: 1653-1659, 2000.
28. Sellke FW, Armstrong ML, and Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the microcirculation of atherosclerotic primates. Circulation 81: 1586-1593, 1990.
29. Sukhova GK, Williams JK, and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22: 1452-1458, 2002.
30. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, and Iguchi A. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155: 347-357, 2001.
31. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000.
32. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, and Kubler W. Dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 102: 2172-2179, 2000.
33. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, and Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 285: H59-H64, 2003.
34. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89: 3A-9A, 2002.
35. Wassmann S, Hilgers S, Laufs U, Bohm M, and Nickenig G. Angiotension II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 22: 1208-1212, 2002.
36. Wilmink HW, Banga JD, Hijmering M, Erkelens WD, Stroes ES, and Rabelink TJ. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 34: 140-145, 1999.
37. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, and Hamilton G. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vac Endovasc Surg 23: 358-364, 2002.
38. Zeiher AM, Drexler H, Saurbier B, and Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92: 652-662, 1993.